The spectrum of giant cell arteritis through a rheumatology lens. [Review]

Khalique, MI.; Arjunan, M.; Wood, S.; Mackie, SL.

The spectrum of giant cell arteritis through a rheumatology lens. [Review]

All Authors

Khalique, MI.

Arjunan, M.

Wood, S.

Mackie, SL.

LTHT Author

Khalique, Muhammad Irfan
Arjunan, Mousindha
Wood, Samuel
Mackie, Sarah
Mackie, Sarah

LTHT Department

Rheumatology
Ophthalmology
NIHR Leeds Biomedical Research Centre

Publication Date

2024

Item Type

Journal Article
Review

Abstract

Treatment of giant cell arteritis (GCA) aims initially to prevent acute visual loss, and subsequently to optimise long-term quality of life. Initial prevention of acute visual loss in GCA is well-standardised with high-dose glucocorticoid therapy but in the longer term optimising quality of life requires tailoring of treatment to the individual. The licensing of the IL-6 receptor inhibitor tocilizumab combined with advances in vascular imaging have resulted in many changes to diagnostic and therapeutic practice. Firstly, GCA is a systemic disease that may involve multiple vascular territories and present in diverse ways. Broadening of the "spectrum" of what is called GCA has been crystallised in the 2022 GCA classification criteria. Secondly, the vascular inflammation of GCA frequently co-exists with the extracapsular musculoskeletal inflammation of the related disease, polymyalgia rheumatica (PMR). Thirdly, GCA care must often be delivered across multiple specialities and healthcare organisations requiring effective interprofessional communication. Fourthly, both GCA and PMR may follow a chronic or multiphasic disease course; long-term management must be tailored to the individual patient's needs. In this article we focus on some areas of current rheumatology practice that ophthalmologists need to be aware of, including comprehensive assessment of extra-ocular symptoms, physical signs and laboratory markers; advanced imaging techniques; and implications for multi-speciality collaboration.